Gapping up
In reaction to strong earnings/guidance: SYMX +21.2%, LAKE +13.6%, MLHR +11.2%
M&A news: CVC +16.5% (Cablevision to be acquired by Altice (ATCEY) for $34.90 in cash, or ~$17.7 bln), WMB +1.2% (Bloomberg reporting co is close to being acquired by Energy Transfer Equity LP (ETE))
Other news: CANF +39.3% (announces Fast Track Designation for its CF102 in the Treatment of Liver Cancer), TGTX +15.2% (reaches an agreement with the FDA for a Special Protocol Assessment on the design of its Phase 3 clinical trial of TG-110), YGE +11.1% (enters into an agreement with CFC Group Construction Limited, to supply 170 MW of solar panels for utility-scale power plants in China's Hebei province), APRI +9.7% (reports top-line Phase 2a data for RayVa; no significant safety or tolerability issues observed), SQNM +8.7% (signs a national agreement with UnitedHealthcare Insurance Company), REN +6.7% (announced agreement to sell its Hilight Field assets in the Wyoming Powder River Basin for $55 mln; proceeds to be used to reduce debt), EGY +3.5% (reported that its North Tchibala 1-H well has been brought online at a rate slightly in excess of 3,000 gross barrels of oil per day), RLYP +3.2% (announced results of Phase 1 Phase 1 onset-of-action study of Patiromer for Oral Suspension were published in Kidney International; Patiromer FOS rapidly and significantly reduced blood potassium from baseline levels in patients with moderate-to-severe hyperkalemia), APD +3.1% (announces Intent to spin-off Materials Technologies Business), NETE +2% (co closed on $1.59 mln of insider financing), AEO +1.7% (Exec Chairman & Interim CEO disclosed purchase of 500K shares, worth total of $7.87 mln), AEO +1.7% (co's Exec Chairman & Interim CEO disclosed purchase of 500K shares, worth total of $7.87 mln), OCRX +1.4% (announced initiation of Phase 1 clinical trial in healthy subjects to evaluate oral prototype solid-dose, extended-release formulations of OCR-002)
Analyst comments: ITCI +6.6% (target raised to $62 at RBC Capital Mkts), MXL +1.7% (upgraded to Buy from Neutral at Needham), NVDA +1.3% (upgraded to Buy from Hold at Jefferies)
In reaction to strong earnings/guidance: SYMX +21.2%, LAKE +13.6%, MLHR +11.2%
M&A news: CVC +16.5% (Cablevision to be acquired by Altice (ATCEY) for $34.90 in cash, or ~$17.7 bln), WMB +1.2% (Bloomberg reporting co is close to being acquired by Energy Transfer Equity LP (ETE))
Other news: CANF +39.3% (announces Fast Track Designation for its CF102 in the Treatment of Liver Cancer), TGTX +15.2% (reaches an agreement with the FDA for a Special Protocol Assessment on the design of its Phase 3 clinical trial of TG-110), YGE +11.1% (enters into an agreement with CFC Group Construction Limited, to supply 170 MW of solar panels for utility-scale power plants in China's Hebei province), APRI +9.7% (reports top-line Phase 2a data for RayVa; no significant safety or tolerability issues observed), SQNM +8.7% (signs a national agreement with UnitedHealthcare Insurance Company), REN +6.7% (announced agreement to sell its Hilight Field assets in the Wyoming Powder River Basin for $55 mln; proceeds to be used to reduce debt), EGY +3.5% (reported that its North Tchibala 1-H well has been brought online at a rate slightly in excess of 3,000 gross barrels of oil per day), RLYP +3.2% (announced results of Phase 1 Phase 1 onset-of-action study of Patiromer for Oral Suspension were published in Kidney International; Patiromer FOS rapidly and significantly reduced blood potassium from baseline levels in patients with moderate-to-severe hyperkalemia), APD +3.1% (announces Intent to spin-off Materials Technologies Business), NETE +2% (co closed on $1.59 mln of insider financing), AEO +1.7% (Exec Chairman & Interim CEO disclosed purchase of 500K shares, worth total of $7.87 mln), AEO +1.7% (co's Exec Chairman & Interim CEO disclosed purchase of 500K shares, worth total of $7.87 mln), OCRX +1.4% (announced initiation of Phase 1 clinical trial in healthy subjects to evaluate oral prototype solid-dose, extended-release formulations of OCR-002)
Analyst comments: ITCI +6.6% (target raised to $62 at RBC Capital Mkts), MXL +1.7% (upgraded to Buy from Neutral at Needham), NVDA +1.3% (upgraded to Buy from Hold at Jefferies)